Effect of Quadripulse Transcranial Magnetic Stimulation in Alcohol Dependance

Not Applicable

• Conditions: Health Condition 1: F102- Alcohol dependence

• Registration Number: CTRI/2023/05/052515
• Lead Sponsor: Central Institute of Psychiatry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients diagnosed with F10.24 Mental and behavioural disorders due to use of alcohol,

dependence syndrome, currently using the substance [active dependence]

2. Last intake of alcohol at least 6 hours before admission, self-reported and corroborated

by informants

3. Male

4. Age between 18 and 50 years

5. Ready to give informed consent

6. Right-handed

7. Drug naïve, Electroconvulsive Therapy naïve, and drug free of any psychotropic

medications for at least 4 weeks.

Exclusion Criteria

1. Age <18 years or >50 years

2. Not willing to give informed consent

3. Any other co-morbid substance abuse except nicotine and caffeine

4. Participants having any co-morbid psychiatric disorders

5. Patients having metallic implant

6. Patients having known contraindication to undergoing Quadripulse Stimulation or fMRI

7. Patient on any anti craving medication during study period and preceding 4 weeks.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Change in score of alcohol craving questionnaire (ACQ-NOW) from baseline to end of <br/ ><br>last QPS sessions and after 28 days from last QPS session <br/ ><br>2. Change in score of obsessive-compulsive drinking scale (OCDUS) from baseline to end <br/ ><br>of last QPS sessions and after 28 days from last QPS session <br/ ><br>3. Change in CIWA-Ar scores baseline to end of last QPS session <br/ ><br>4. Number of days to reach CIWA-Ar score 10Timepoint: Baseline (day2) <br/ ><br>ACQ-NOW, OCDUS, HAM-A, HAM-D (day8) <br/ ><br>CGI-I, CIWA-Ar (day3, 4, 5, 6, 7, 8) <br/ ><br>all of the above (day 35)

Secondary Outcome Measures

Name	Time	Method
1. Change in resting state functional connectivity of executive control network and <br/ ><br>salience ventral attention network from baseline to end of last QPS sessions. <br/ ><br>2. Change in cue related functional connectivity of executive control network and salience <br/ ><br>ventral attention network baseline to end of last QPS sessions. <br/ ><br>3. Dosage of benzodiazepines required during detoxification (baseline to CIWA-Ar 10) <br/ ><br>4. Changes in CGI-I scores from baselineTimepoint: day0 day7